世界のADC（抗体－薬物複合体）市場展望（～2018）...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) – An Introduction
4. ADC Market Outlook to 2018
4.1 Adcetris
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2018
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2018
5. Current Status and Potential of Key ADC in Pipeline
5.1 Inotuzumab Ozogamicin/CMC-544 – Pfizer
5.2 Glembatumumab Vedotin/CDX-011 – Celldex Therapeutics
5.3 SAR-3419 – Sanofi
5.4 PSMA-ADC – Progenics Pharmaceuticals
5.5 RG-7596 – Roche
5.6 RG-7593 – Roche
6. Strategic Collaborations in the ADC Industry
7. Drivers and Challenges
8. Competitive Landscape
8.1 Roche
8.2 Sanofi
8.3 Progenics
8.4 Seattle Genetics
8.5 Celldex Therapeutics

List of Figures

Figure 3 1: ADC – Mechanism of Action
Figure 4 1: Global – ADC Market (Million US$), 2013 & 2018
Figure 4 2: Global – Adcetris Market (Million US$), 2011 & 2012
Figure 4 3: Global – Adcetris Market (Million US$), 2013 & 2018
Figure 4 4: Global – Kadcyla Market (Million US$), 2013 & 2018

List of Tables

Table 4 1: Potential Patients for Adcetris (2012)
Table 4 2: Ongoing Trials for Adcetris
Table 4 3: Potential Patients for Kadcyla (2012)
Table 4 4: Ongoing Trials for Kadcyla
Table 5 1: ADCs in Pipeline
Table 6 1: Strategic Collaborations in the ADC Industry
Table 8 1: Roche – ADCs in Pipeline
Table 8 2: Roche – Strengths and Weaknesses
Table 8 3: Sanofi – ADCs in Pipeline
Table 8 4: Sanofi – Strengths and Weaknesses
Table 8 5: Progenics – ADCs in Pipeline
Table 8 6: Progenics – Strengths and Weaknesses
Table 8 7: Seattle – ADCs in Pipeline
Table 8 8: Seattle Genetics – ADC Collaborator Pipeline
Table 8 9: Seattle – Strengths and Weaknesses
Table 8 10: Celldex Therapeutics – ADC Pipeline
Table 8 11: Celldex Therapeutics – Strengths and Weaknesses